LCM
REGN icon

Liberty Capital Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Liberty Capital Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-410
Closed -$209K – 96
2015
Q2 		$209K Buy
+410
New +$200K 0.14% 100

Other funds holding REGN

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

Liberty Capital Management's REGN Position: Q3 2015 in Review

Liberty Capital Management sold out of Regeneron Pharmaceuticals (REGN) in Q3 2015, closing a stake of 410 shares — an estimated $209K sold.

Liberty Capital Management first reported a position in REGN in Q2 2015 and held it in 1 quarter. The position peaked at $209K in Q2 2015. 563 funds tracked by Wall St. Rank hold REGN as of Q3 2015.

  • Liberty Capital Management reported no remaining Regeneron Pharmaceuticals position as of Q3 2015 after selling out during the quarter.
  • Liberty Capital Management sold 410 Regeneron Pharmaceuticals shares in Q3 2015, an estimated $209K.
  • Liberty Capital Management first reported a position in Regeneron Pharmaceuticals in Q2 2015 and held it in 1 quarter.
  • Liberty Capital Management's Regeneron Pharmaceuticals position peaked at $209K in Q2 2015.
  • 563 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2015.

Based on Liberty Capital Management's 13F filing for Q3 2015, filed 6 Oct 2015.